Life Sciences Crowdfunding Platform Capital Cell Opens to UK Investors

Capital Cell, a crowdfunding platform dedicated to life sciences, announced this week it is officially opening its portal to UK investors. The first four investment opportunities now live on the platform.

As previously reported, Capital Cell was founded by Daniel Oliver and based in Barcelona, is the first European equity crowdfunding platform for Biotech projects.  After several successful years of investment crowdfunding in Spain specializing in life science, Capital Cell has jumped the Channel and expanded into the UK market. The platform claims it carefully selects high-quality scientific investment opportunities for investors. Capital Cell has raised over €4.4M for research and development in various branches of life science, including biotechnology, medical devices, therapeutics, genomics and drug discovery.

Capital Cell is backed in its expansion by a number of leading UK life sciences innovators and investors, which includes Dr. Harren Jhoti, founder and CEO of Astex Pharmaceuticals; life sciences angel investor David Ford; Adrian Parton, MBE, of Boundary Capital and serial life sciences entrepreneurs Sunil and Prashant Shah of O2h Ventures. Dr. Ian Tomlinson – founder of Domantis, sold to GSK. Tomlinson stated:

“Having spent my career in life sciences, the opportunity to become a part of the next wave of funding for the sector is very exciting. UK innovation is amongst the best in the world: with the support Capital Cell seeks to provide for early stage companies, start-ups and spin-outs can look to the future with confidence. Capital Cell, and crowdfunding more generally, provides an answer to a funding gap which has been becoming more obvious for some time. Following its successful start to life in Spain, Capital Cell is well set for success in the UK.”

Dr. Laura Ferguson, UK director of Capital Cell, also commented:

“Investing in private life sciences companies has traditionally only been available to highly sophisticated investors with significant technical expertise and large sums to invest. Whilst investing in early stage companies will always involve significant risks, Capital Cell’s unique screening process and new investment platform opens up opportunities to everyone. If the companies are successful in achieving their goals the financial rewards for investors can be significant and the social impact can affect the lives of millions.”

Capital Cell went on to add that it is based in proximity to 33% of the UK’s biotech companies, 10% of the entire total in Europe.

Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!

Sponsored Links by DQ Promote



Send this to a friend